Evidence map›Paper›PMID 33983671›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2021

Renal allograft DARCness in subclinical acute and chronic active ABMR.

Johannes Kläger, Farsad Eskandary, Georg A Böhmig, Nicolas Kozakowski, Alexander Kainz, Yves Colin Aronovicz, Jean-Pierre Cartron, Stephan Segerer, Heinz Regele

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01873157 (Bortezomib in Late Antibody-mediated Kidney Transplant Rejection), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01873157 phase2completednot on this map

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)

TypeinterventionalSponsorMedical University of ViennaRan2013 to 2017Enrolled44ConditionsLate Rejection of Renal Transplant, Antibody-mediated RejectionArmsBortezomib, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. DARC and Anti-Duffy Antibodies in the Line of Fire: The Challenges in Pinpointing the Etiology of Microcirculation Inflammation to a Distinct Entity.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Johannes KlägerDepartment of Pathology, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-5761-0713
Farsad EskandaryDivision of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-8971-6149
Georg A BöhmigDivision of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-7600-912X
Nicolas KozakowskiDepartment of Pathology, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-9180-620X
Alexander KainzDivision of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8888-440X
Yves Colin AronoviczLaboratoire d'Excellence GR-Ex, Paris, France.ORCID https://orcid.org/0000-0001-5196-4254
Jean-Pierre CartronUniversité Sorbonne Paris Cité, Université Paris Diderot, Inserm U1134, Institut National de la Transfusion Sanguine, Unité Biologie Intégrée du Globule Rouge, Paris, France.ORCID https://orcid.org/0000-0003-2929-3065
Stephan SegererDivision of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland.ORCID https://orcid.org/0000-0002-1936-9719
Heinz RegeleDepartment of Pathology, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-2929-6135
Medical University of Vienna · ATInserm · FRInstitut National de la Transfusion Sanguine · FRKantonsspital Aarau · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene expression profiling of renal allograft biopsies revealed the Duffy antigen receptor for chemokines (DARC) as being strikingly upregulated in antibody-mediated rejection (ABMR). DARC has previously been shown to be associated with endothelial injury. This study aimed at assessing the value of DARC immunohistochemistry as diagnostic marker in ABMR. The study was performed on 82 prospectively collected biopsies of a clinically well-defined population (BORTEJECT trial, NCT01873157) of DSA-positive patients with gene expression data available for all biopsies. Diagnostic histologic assessment of biopsies was performed according to the Banff diagnostic scheme. DARC expression was focally accentuated, on peritubular capillaries (PTC) mostly in areas of interstitial fibrosis and/or inflammation. DARC positivity was associated with diagnosis of ABMR and correlated with DARC gene expression levels detected by microarray analysis. Still, as previously described, a substantial number of biopsies without signs of rejection showed DARC-positive PTC. We did not observe significantly reduced graft survival in cases showing histologic signs of ABMR and being DARC-positive, as compared to DARC-negative ABMR. In summary, the upregulation of DARC, detected by immunohistochemistry, is associated with but not specific for ABMR. We did not observe reduced graft survival in DARC-positive patients.

Indexed as

Kidney TransplantationAllograftsGraft RejectionHumansIsoantibodiesKidneyIsoantibodiesantibody-mediated rejectionDuffy antigen receptor for chemokinesimmunohistochemistry gene expression profilingkidney transplantation

Identifiers

PMID33983671
PMCPMC8453966
OpenAlexW3163335298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.